Insulin detemir used in basal‐bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin
Year: 2004
Type: article
Study design: Clinical Trial
Source: Diabetes Obesity and Metabolism
Authors: I. De Leeuw, P. Vague, J.‐L. Selam, S. Skeie, H. Lang, E. Draeger, J. W. F. Elte
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Novo Nordisk
OpenAlex ID: W2054412998
